ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.641,30
0,25%
S&P 500
5.477,90
0,16%
US Dollar vs BRL
5,5242
0,00%
Bitcoin
60.747,96
-0,11%
Brent Oil
84,335
-0,16%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Innate Pharma SA (IPHA)

  7. Innate Pharma SA (IPHA) Notícias

IPHA

Innate Pharma (IPHA)

Innate Pharma SA
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:IPHA
DataHoraFonteTítuloCódigoCompanhia
18/06/202402:00Business WireNouveau nombre d’actions et de droits de vote d’Innate Pharma au 10 juin 2024NASDAQ:IPHAInnate Pharma SA
18/06/202402:00Business WireNumber of Shares and Voting Rights of Innate Pharma as of June 10, 2024NASDAQ:IPHAInnate Pharma SA
17/06/202402:00Business WireInnate Pharma partage de nouveaux résultats concernant l’essai de Phase 1/2 mené par Sanofi évaluant le NK cell engager SAR443579/IPH6101 dans divers cancers du sangNASDAQ:IPHAInnate Pharma SA
17/06/202402:00Business WireInnate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 TrialNASDAQ:IPHAInnate Pharma SA
04/06/202407:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPHAInnate Pharma SA
04/06/202402:00Business WireInnate Pharma présente les résultats positifs de l’étude de Phase 2 TELLOMAK évaluant lacutamab dans le mycosis fongoïdeNASDAQ:IPHAInnate Pharma SA
04/06/202402:00Business WireInnate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis FungoidesNASDAQ:IPHAInnate Pharma SA
28/05/202402:00Business WireInnate Pharma Announces Its Participation in Upcoming Investor ConferencesNASDAQ:IPHAInnate Pharma SA
28/05/202402:00Business WireInnate Pharma annonce sa participation à de prochaines conférences investisseursNASDAQ:IPHAInnate Pharma SA
24/05/202402:00Business WireInnate Pharma Highlights Abstracts Selected for ASCO 2024 Annual MeetingNASDAQ:IPHAInnate Pharma SA
24/05/202402:00Business WireInnate Pharma partage les abstracts sélectionnés pour le congres annuel de l’ASCO 2024NASDAQ:IPHAInnate Pharma SA
23/05/202417:00Business WireOutcome of Innate Pharma’s 2024 Annual General MeetingNASDAQ:IPHAInnate Pharma SA
23/05/202417:00Business WireRésultats de l’Assemblée Générale mixte du 23 mai 2024NASDAQ:IPHAInnate Pharma SA
21/05/202402:00Business WireInnate Pharma: Clarification Regarding SAR443579 DesignationNASDAQ:IPHAInnate Pharma SA
21/05/202402:00Business WireInnate Pharma: Clarification concernant le statut de SAR443579NASDAQ:IPHAInnate Pharma SA
15/05/202402:00Business WireInnate Pharma partage les abstracts sélectionnés pour le congrès 2024 de l’EHANASDAQ:IPHAInnate Pharma SA
15/05/202402:00Business WireInnate Pharma Highlights Abstracts Selected for EHA 2024 CongressNASDAQ:IPHAInnate Pharma SA
14/05/202402:00Business WireInnate Pharma Reports First Quarter 2024 Business Update and Financial ResultsNASDAQ:IPHAInnate Pharma SA
14/05/202402:00Business WireInnate Pharma fait le point sur ses activités et publie ses résultats financiers pour le premier trimestre 2024NASDAQ:IPHAInnate Pharma SA
07/05/202402:00Business WireInnate Pharma Announces Conference Call and Webcast for Q1 2024 Business UpdateNASDAQ:IPHAInnate Pharma SA
07/05/202402:00Business WireInnate Pharma organise une conférence téléphonique pour présenter ses résultats au premier trimestre 2024NASDAQ:IPHAInnate Pharma SA
15/04/202402:00Business WireInnate Pharma annonce la progression de l’essai clinique évaluant le NK Cell Engager SAR443579 / IPH6101 développé par Sanofi vers la Phase 2 dans divers cancers du sangNASDAQ:IPHAInnate Pharma SA
15/04/202402:00Business WireInnate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer PatientsNASDAQ:IPHAInnate Pharma SA
15/04/202402:00Business WireL’Assemblée Générale d’Innate Pharma aura lieu le 23 mai 2024NASDAQ:IPHAInnate Pharma SA
15/04/202402:00Business WireInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024NASDAQ:IPHAInnate Pharma SA
10/04/202402:00Business WireInnate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug ConjugateNASDAQ:IPHAInnate Pharma SA
10/04/202402:00Business WireInnate Pharma présente des données d’efficacité précliniques pour IPH45, son conjugué anticorps-médicament innovant ciblant nectine-4 a l’AACR 2024NASDAQ:IPHAInnate Pharma SA
09/04/202402:00Business WireInnate Pharma annonce sa participation à une prochaine Conférence InvestisseursNASDAQ:IPHAInnate Pharma SA
09/04/202402:00Business WireInnate Pharma Announces Its Participation in Upcoming Investor ConferenceNASDAQ:IPHAInnate Pharma SA
05/04/202404:34Business WireInnate Pharma publie son Document D’enregistrement Universel 2023 et son Rapport Annuel 2023 sur « Form 20-F »NASDAQ:IPHAInnate Pharma SA
 Apresentando as notícias mais relevantes sobre:NASDAQ:IPHA

Seu Histórico Recente

USOTC
ETOLF
Enterprise (QB)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados